copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Povetacicept, an Enhanced Dual APRIL BAFF Antagonist That . . . - PubMed Results: Povetacicept inhibited APRIL and BAFF more effectively than all evaluated forms of WT TACI-Fc and selective APRIL and BAFF inhibitors in cell-based reporter assays and primary human B cell assays, mediating potent suppression of B cell proliferation, differentiation, and immunoglobulin (Ig) secretion
Povetacicept, an Enhanced Dual APRIL BAFF . . . - Wiley Online Library Dysregulated APRIL BAFF signaling is implicated in the pathogenesis of multiple autoimmune diseases, including SLE and LN A high affinity APRIL BAFF antagonist was developed to overcome the clinical limitations of existing B cell inhibitors
Povetacicept (ALPN-303), a Potent Dual BAFF APRIL Antagonist . . . Povetacicept is an Fc fusion protein of an engineered TACI domain which mediates significantly more potent dual inhibition of APRIL and BAFF than WT TACI-Fc, which has shown promise in the treatment of myasthenia gravis and other antibody-related diseases
Povetacicept, an Enhanced Dual APRIL BAFF Antagonist that Modulates B . . . Dysregulated APRIL BAFF signaling is implicated in the pathogenesis of multiple autoimmune diseases, including SLE and LN A high affinity APRIL BAFF antagonist was developed to overcome the clinical limitations of existing B cell inhibitors
OP0282â POVETACICEPT (ALPN-303; TACI vTD-Fc), AN ENHANCED, POTENT DUAL . . . Mice were analyzed 7 weeks later for disease endpoints, including proteinuria, nephritis, and anemia Results: In publicly available transcriptional datasets, PBMC from SLE patients exhibit a significant elevation of BAFF and or APRIL compared to healthy adults
Povetacicept, an Enhanced Dual APRIL BAFF Antagonist That Modulates B . . . We undertook this study to develop and evaluate a high-affinity APRIL BAFF antagonist to overcome the clinical limitations of existing B cell inhibitors A variant of TACI-Fc generated by directed evolution showed enhanced binding for both APRIL and BAFF and was designated povetacicept (ALPN-303)
OP0282 POVETACICEPT (ALPN-303; TACI vTD-Fc), AN ENHANCED, POTENT DUAL . . . Objectives: 1 To investigate the impact of povetacicept on gene expression in human peripheral blood mononuclear cells (PBMC) stimulated in vitro with BAFF and or APRIL 2 To compare the tissue distribution of povetacicept following a single dose to WT TACI-Fc (telitacicept) in adult mice